• Neurocrine Biosciences (NasdaqGS:NBIX) reported new data on INGREZZA showing strong symptom improvements in tardive dyskinesia for patients with intellectual and developmental disabilities.
• Additional analyses indicated meaningful benefits and remission rates in patients with hepatic impairment, a group that often faces limited dosing options.
• The findings highlight functional gains and rapid symptom relief in challenging real world populations beyond the broader tardive dyskinesia group.

For investors watching Neurocrine Biosciences, the update on INGREZZA adds a fresh angle to the story around its core commercial asset. The stock trades at $160.86 and has gained 14.4% year to date and 29.5% over the past year, with a value score of 3. This news comes after recent attention on rare disease strategy and CRENESSITY data, giving you another piece of information on how the existing portfolio is being used in practice.

What stands out here is INGREZZA's applicability in patient segments that are often harder to study or treat, such as those with intellectual and developmental disabilities or hepatic risk factors. For readers tracking NasdaqGS:NBIX, this may be useful context when assessing how the INGREZZA franchise is being applied across different real world settings.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Quick Assessment

• ✅ Price vs Analyst Target: At US$160.86, the stock sits about 17% below the US$192.88 analyst price target.
• ✅ Simply Wall St Valuation: Classified as undervalued, trading around 64% below one estimated fair value.
• ✅ Recent Momentum: A 30 day return of 6.8% indicates the share price has been moving higher recently.

There's only one way to know the right time to buy, sell or hold Neurocrine Biosciences. Head to Simply Wall St's company report for the latest analysis of Neurocrine Biosciences's Fair Value.

Key Considerations

• 📊 INGREZZA data in harder to treat populations reinforces how central this product is to the revenue and earnings story.
• 📊 Monitor ongoing INGREZZA data releases, prescription trends, and any label or guideline updates linked to intellectual disability or hepatic impairment groups.
• ⚠️ Even with no flagged company specific risks, investors may wish to consider trial replication, competitive treatments, and payer decisions as key uncertainties around this news.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Neurocrine Biosciences analysis. Alternatively, you can check out the community page for Neurocrine Biosciences to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.